Recombinant Human Granulocyte Colony-Stimulating Factor Mobilized Human Peripheral Blood Monocytes Derived Dendritic Cell Vaccine As a Tumor Immunotherapy
CAI Kai,GAO Yan-rong,KE Yan,ZHANG Da-liang,MA Li-hua,XUE Hui,JIA Shao-chang
DOI: https://doi.org/10.3969/j.issn.1008-8199.2012.06.013
2012-01-01
Abstract:Objective The purpose of this study was to investigate the feasibility of clinical application of recombinant human granulocyte colony-stimulating factor(rhG-CSF)-mobilized monocytes(Mo) derived dendritic cell(DC) vaccine.Methods We retrospectively nanalyzed 59 cases of tumor treated by Mo-DC vaccine therapy,of whom 32 were mobilized with rhG-CSF,and the other 27 unmobilized as controls.For the mobilized group,rhG-CSF was injected subcutaneously(1.25 μg/kg/24 h×1 d or×2 d or ×3 d) before apheresis using a blood cell separator,and blood routine examinations were performed before and after mobilization.Comparisons were made between the mobilized and control groups in collection efficiency and the number and viability of mononuclear cells in the final apheresis products,as well as in the count,yield rate,purity and viability of Mo-DCs under the same collection circulating volume.The phenotypes of the Mo-DCs were determined by FCM and concentrations of cytokines IL-12,IFN-γ and IL-10 in the cell culture supernatants were measured by ELISA.Results After 3 days of rhG-CSF mobilization,the Mo count in the peripheral blood was significantly increased as compared with the baseline(P0.05).There were significant differences between the mobilized and control groups in the number of mononuclear cells in the final apheresis products(P0.05),but not in the collection efficiency,platelet loss viability of mononuclear cells.The Mo-DC yield was significantly higher in the mobilized group than in the control(P0.05),but no significant differences were found in the Mo-DC yield rate,purity and viability between the two groups,nor in the expressions of HLA-DR,CD11c,CD80,CD86,CD83 and CD54,and in the concentrations of cytokines IL-12,IFN-γ and IL-10 in the cell culture supernatants.Conclusion rhG-CSF mobilization for tumor patients receiving Mo-DC vaccine therapy for at least 3 consecutive days before apheresis could efficiently improve the Mo-DC vaccine yield and hence the outcome of vaccine therapy.